PMID- 34540463
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210921
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 13
IP  - 8
DP  - 2021 Aug
TI  - Effectiveness of Stem Cell Therapies in Improving Clinical Outcomes in Patients 
      With Heart Failure.
PG  - e17236
LID - 10.7759/cureus.17236 [doi]
LID - e17236
AB  - Heart failure (HF), continuing to be a notable cause of morbidity and mortality 
      worldwide, also is a noteworthy economic burden to the patients. Current medical 
      management of HF has poor efficacy to completely arrest or reverse the 
      progression to end-stage disease. As the option of cardiac transplantation 
      remains limited to few patients, the stem cell approach continues to be a 
      promising one in developing a novel therapy in the treatment of HF. This review 
      attempts to discuss and compare the outcomes of numerous clinical trials that 
      involved treatment of HF of variable etiologies with stem cells of numerous 
      lineages such as bone marrow-derived cells (BMCs), mesenchymal stem cells (MSCs), 
      cardiosphere derived progenitor cells (CDCs), etc. We reviewed articles and 
      randomized controlled trials (RCT) that used stem cells to treat heart failure. 
      The articles and RCT studies were obtained through a search on PubMed and Medline 
      databases and performed using regular and medical subject heading (MeSH) keyword 
      search strategy. A total of 17 trial-based studies, along with other articles 
      that met the aim of the review, were selected. A discussion of the findings from 
      major clinical trials such as the C-CURE, CHART-1, POSEIDON, POSEIDON-DCM, 
      TAC-HFT, and other small scale trials highlights the change in functional and 
      mechanical parameters of HF, namely, left ventricular ejection fraction (LVEF), 
      end-diastolic volume (EDV), end-systolic volume (ESV), 6-minute walking test 
      distance (6MWTD), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 
      and assessment of New York heart association (NYHA) class of heart failure, and 
      Minnesota Living with Heart Failure Questionnaire (MLHFQ) score to reflect 
      improvement in quality of life (QoL) of patients. Out of the studies analyzed, 
      the majority reported significant improvements in at least two of the parameters 
      mentioned above. However, more phase three randomized trials are required to 
      compare the efficacy of multiple lineages of stem cells, factoring in molecular 
      and dosage factors to develop a standardized therapy.
CI  - Copyright (c) 2021, Bhawnani et al.
FAU - Bhawnani, Nitin
AU  - Bhawnani N
AD  - Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Ethirajulu, Aarthi
AU  - Ethirajulu A
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Alkasabera, Almothana
AU  - Alkasabera A
AD  - General Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Onyali, Chike B
AU  - Onyali CB
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Anim-Koranteng, Comfort
AU  - Anim-Koranteng C
AD  - Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Shah, Hira E
AU  - Shah HE
AD  - Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Mostafa, Jihan A
AU  - Mostafa JA
AD  - Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210816
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8447853
OTO - NOTNLM
OT  - clinical outcomes
OT  - heart failure
OT  - heart failure outcomes
OT  - stem cell
OT  - stem cell therapy effectiveness
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/09/21 06:00
MHDA- 2021/09/21 06:01
PMCR- 2021/08/16
CRDT- 2021/09/20 06:10
PHST- 2021/07/07 00:00 [received]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/09/20 06:10 [entrez]
PHST- 2021/09/21 06:00 [pubmed]
PHST- 2021/09/21 06:01 [medline]
PHST- 2021/08/16 00:00 [pmc-release]
AID - 10.7759/cureus.17236 [doi]
PST - epublish
SO  - Cureus. 2021 Aug 16;13(8):e17236. doi: 10.7759/cureus.17236. eCollection 2021 
      Aug.